STERIS Earnings Call Transcripts
Fiscal Year 2026
-
Record fiscal 2026 results featured 9% revenue growth and 10% adjusted EPS growth, with all segments achieving milestones. Fiscal 2027 guidance calls for 7%-8% revenue growth, 9%-11% EPS growth, and continued investment in automation, M&A, and share buybacks.
-
Q3 saw 9% revenue growth and 9% EPS growth, with strong segment performance and robust free cash flow, despite significant tariff headwinds. Fiscal 2026 guidance is maintained, with ongoing mitigation efforts for tariffs and continued strength in capital equipment backlogs.
-
Second quarter revenue grew 10% year-over-year, with strong margin expansion and 15% EPS growth. All segments delivered robust organic growth, and full-year guidance was raised for revenue, earnings, and free cash flow.
-
First quarter results showed 9% revenue growth and 15% higher adjusted EPS, with strong performance across all segments and a raised free cash flow outlook. Tariff costs increased but were offset by favorable FX, and a CFO transition was announced.
Fiscal Year 2025
-
Q4 and full-year results showed strong revenue and double-digit earnings growth, with margin expansion and record free cash flow. Fiscal 2026 guidance calls for 6%-7% revenue growth and 7%-10% EPS growth, despite $30 million in tariff costs and a $40 million legal settlement.
-
Revenue and organic growth reached 6% year-over-year, with strong recurring revenue and margin gains across segments. Adjusted EPS rose 11%, and free cash flow is on track for $700 million. Litigation and currency headwinds persist, but order growth and backlog remain robust.
-
Second quarter revenue and adjusted EPS grew 7% and 15% year-over-year, respectively, with strong recurring revenue in healthcare and robust order growth. Full-year guidance for revenue and EPS was reiterated, while margins are expected to be flat due to cost pressures and a one-time AST loss.
-
Revenue grew 8% year-over-year in Q1, with strong gains in consumables and services offsetting capital equipment declines. Adjusted EPS rose 10%, and full-year guidance for 6%-7% organic revenue growth and $9.05-$9.25 EPS was reiterated. Free cash flow and dividend growth remain robust.
Fiscal Year 2024
-
U.S. healthcare procedure volumes are strong, with Europe showing improving trends. Recurring revenue now dominates, offsetting expected modest growth in capital equipment. Strategic focus includes digitalization, compliance, and continued market share gains, with leadership continuity supporting long-term performance.